Navigation Links
Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Date:5/2/2011

PLYMOUTH, Mich., May 2, 2011 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.  In the Phase 1 study, treatment with ETC-1002 was shown to be safe and well tolerated and to significantly reduce LDL-C levels in subjects with mild dyslipidemia.

ETC-1002, the company's lead product candidate, is a novel small molecule that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism.  It is being developed to treat dyslipidemia and other cardio-metabolic risk factors.  Mechanistic studies indicate that treatment with ETC-1002 increases AMP-kinase phosphorylation, inhibits fatty acid and cholesterol synthesis and also enhances fatty acid oxidation.   In the Phase 1 study, treatment with ETC-1002 resulted in consistent, dose-related reductions in LDL-C.  The randomized, double-blind, placebo-controlled study included 32 subjects treated with daily doses of ETC-1002 up to 120 mg or placebo for 14 days and 21 subjects treated with 120 mg of ETC-1002 or placebo for 28 days.

"Cardio-metabolic diseases remain the number one cause of death in people around the world, and research indicates that an effective agent to manage both plasma lipids and glucose could offer significant benefit to millions of patients.  The results of our Phase 1 study show a statistically significant lowering of LDL-C in mildly dyslipidemic subjects and a favorable safety profile, and serve as a solid foundation for clinical evaluation in patients with other cardio-metabolic abnormalities," said Roger Newton, PhD, President and CEO of Esperion.

In addition to the result
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
2. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
3. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Samplify Systems Announces Availability of Prism FP Floating Point Compression
6. Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
8. BioMarin Announces First Quarter 2011 Financial Results
9. IRIDEX Announces First Quarter 2011 Conference Call and Release Date
10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
11. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... leading biopharmaceutical company dedicated to the research and development ... disorders, is marking Digestive Disease Week (DDW) 2012 in ... lives of patients with Crohn,s disease. UCB will present ... "DDW is an exciting opportunity for UCB to ...
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and segments the ... forecast. The well intervention services market in Europe is estimated ... billion by 2018, at a CAGR of 7% from 2013 ... Well Intervention Market report, to get an idea of the ... segmentation in the Europe well intervention market, and is supported ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Alliance ... nation’s only non-profit dedicated exclusively to cell and ... Joshua Corday has joined the organization as Senior ... professional with deep experience securing gifts and addressing ... as Annual Giving Director for NewYork Presbyterian Hospital/Columbia ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... ... scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, ... and clinical development. , ... Minneapolis, Minnesota (PRWEB) November 4, 2009 -- Arrowhead’s 2010 Allosteric and Orthosteric Modulator ...
... Sports ... branded hand sanitizer. , ... 2009 -- Sports fans old and young, can fend off germs and show their team spirit by ... team branded hand sanitizer is available in a kleen kit that consists of a 2 ...
... ... Data Center, combined with the hosting and managed services that the ... York competitive. The company,s new high availability data center allows businesses ... their data and computer services are protected in a state-of-the-art facility. ...
... , CAMPBELL, Calif., Nov. 4 Adaptive Sound Technologies, Inc. ... ASTI customers who refer friends that in turn buy an ... "Tell-a-Friend" program rewards customers for doing what they have been ... letting friends in on the secret to better sleep. , ...
... the increasing complexities of treating digestive diseases, allowing gastroenterological ... and experiences in specific disease areas or procedures will ... "Report of the Multisociety Task Force on GI Training." ... of trainees based on specific defined competencies rather than ...
... TeamStaff, Inc. (Nasdaq: TSTF) , a national ... that the Company has completed an in-depth strategic review of ... government spending, and changing dynamics in the healthcare market. ... committee of the board of directors and the executive management ...
Cached Medicine News:Health News:Leaders in the Study of Allosteric Modulation to Discuss Latest Research at Allosteric and Orthosteric Modulator Congress 2Health News:Keep H1N1 at Bay and Show Team Spirit 2Health News:LogicalSolutions.net Opens New Enterprise Class Datacenter in Rochester, NY 2Health News:LogicalSolutions.net Opens New Enterprise Class Datacenter in Rochester, NY 3Health News:Better Sleep Pays off with Ecotones Duet 2Health News:Better Sleep Pays off with Ecotones Duet 3Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 2Health News:Gastroenterology/hepatology societies release report evaluating fellowship training curriculum 3Health News:TeamStaff Announces Revised Business Strategy; Chief Executive Officer to Step Down on Completion of Search For Successor 2Health News:TeamStaff Announces Revised Business Strategy; Chief Executive Officer to Step Down on Completion of Search For Successor 3
... ELx405 Series of microplate washers are precise, ... patented Dual-Action manifold, providing independent control of ... overfill washing and overflow protection in both ... Washer is the most precise and reliable ...
MW 96-W1 microplate washer with one wash line....
High precision microplate washer for immuno and adherent cell assays. For use with all strip types and full microplate in 96- and 384-well format in both portrait and landscape orientations....
Wellwash 384 is an efficient, rapid and reliable washing process for high-throughput screening. It has been designed to optimize the washing process and ensure the best results. Available in 384 or 9...
Medicine Products: